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Recent work has identiﬁed heterozygous mutations in
DNMT3a in 4.1–22.1% of patients with acute myeloid leukemia
(AML).
1,2 Here we show that 3.3% of patients with high risk
myelodysplastic syndrome (MDS) also possess heterozygous
mutations in the methyltransferase domain of DNMT3a. Our
results suggest that DNMT3a mutations may precede the
development of AML.
MDS is a heterogenous group of clonal bone marrow
disorders characterized by ineffective hematopoiesis, cytopenias
and increased risk of AML. On a cellular level, there is an
increased rate of proliferation accompanied by an increase in
apoptosis. Currently approved treatments include supportive
therapy with transfusion and growth factors followed by disease
modifying agents lenalidomide, and the hypomethylating
agents, azacitidine and decitabine.
3 Azacitidine and decitabine
are often reserved for treatment of patients with high-risk disease
due to their potential toxicities and limited efﬁcacy for lower risk
patients.
3,4 These agents are thought to act by altering aberrant
methylation patterns seen in patients with MDS through
inhibition of the DNA methyltransferases (DNMTs).
4
DNMTs comprise a family of methyltransferase proteins that
catalyze the methylation of cytosine within CpG dinucleotides.
These CpG dinucleotides are frequently found within the
upstream regulatory region of genes and their methylation can
lead to gene silencing.
5 Studies of DNA methylation in cancer
and MDS have shown altered methylation patterns in these
diseases particularly with hypermethylation of tumor suppres-
sors and hypomethylation of proto-oncogenes.
6–8 These epige-
netic changes are possibly due to alteration in the activity or
target speciﬁcity of DNMTs.
Recent studies in AML have found mutations in the DNA
methyltransferase DNMT3a.
1,2 Yamashita et al. reported that
3/74 (4.1%) of AML patients in their series harbored hetero-
zyogous DNMT3a mutations at the R882 position.
1 More
recently, Ley et al. identiﬁed a number of heterozygous
DNMT3a mutations in 62/281 (22.1%) of AML patients in their
series. Although the majority of these mutations affected the
R882 position, additional mutations were identiﬁed. The authors
attribute the discrepancy in mutation frequency to the use of
massively parallel sequencing. Despite the increased frequency
of mutation, the R882 mutations comprised the majority of
DNMT3a mutations and were associated with a signiﬁcantly
worse prognosis.
2
Following the report by Yamashita et al. of heterozygous
mutations within the methyltransferase domain of DNMT3a in
patients with AML,
1 we wondered whether MDS samples also
bear such mutations. If so, such mutations would precede the
development of leukemia and may be important in the
pathogenesis of MDS. We therefore focused on patients with
high risk MDSFincluding refractory anemia with excess blasts I
or II (RAEB-I, RAEBII)Fboth of which carry a high likelihood of
transforming to AML, but do not possess the pathological
features of AML.
The MT domain of DNMT3a contains eight exons. Initially,
we ampliﬁed and sequenced all eight exons from 62 RAEB-I and
RAEBII patients using genomic DNA extracted from bone
marrow samples. We identiﬁed six heterozygous mutations in
ﬁve patients from this sample (Table 1). Two were silent base
pair changes and were not examined further. Two were guanine
to adenosine substitutions resulting in the substitution of
histidine for arginine at amino acid 882 (R882H). One was a
cytosine to thymine substitution resulting in the substitution of
cysteine for arginine at amino acid 882 (R882C) and the last
mutation was a guanine to adenosine substitution resulting in
the substitution of tyrosine for cysteine at amino acid 709
(C709Y). Given that these missense mutations were found
exclusively in the third and seventh amplicons, we ampliﬁed
only these segments in an additional set of 38 RAEB-I and
RAEB-II patients and identiﬁed one additional heterozygous
R882C mutation. In total we identiﬁed four patients who possess
R882 mutations identical to those previously described in AML
and one of these four also harbored a C709Y mutation.
We next determined whether these mutations were somati-
cally derived within the dysplastic marrow of these patients by
examining DNA derived from buccal swabs of the patients.
In principle, buccal DNA should contain the germline
sequence, although saliva is known to be contaminated with
hematopoietic cells (particularly leukocytes).
We ampliﬁed and sequenced the region of R882 and C709.
The R882 mutation was clearly somatic in one of the patients
examined (Figure 1, patient 55). The buccal DNA of patient 37
showed a low ratio of the mutated sequence. We hypothesized
that this low-abundance mutant sequence may be due to
contamination with mutation-bearing hematopoietic cells. To
test this, we repeated the ampliﬁcation and sequencing on a
second buccal swab from patient 37 and found that the mutation
was absent, indicating previous sample contamination and that
the mutation arose somatically within the marrow (Figure 1,
patient 37).
A third patient (68) also possessed the mutant allele in the
buccal swab, but the low ratio of wild type to mutant in the
Table 1 Analysis of bone marrow and buccal DNA showing
somatic missense mutations in patients 37, 55, and 68 and silent
mutations in patients 14 and 33
Patient Diagnosis Mutation Somatic
14 RAEB I Ser892Ser (A4T) Not examined
33 RAEB I Asn717Asn (C4T) Not examined
37 RAEB II Cys709Tyr (G4A)
Arg882Cys (C4T)
Somatic
a
55 RAEB I Arg882His (G4A) Somatic
68 RAEB II Arg882Cys (C4T) Likely
b
aInitial buccal swab shows decreased frequency of mutation from bone
marrow, repeat buccal swab shows clearly that the mutation arose
somatically.
bThere is a decreased frequency of mutation in the buccal swab
compared with the bone marrow but we hypothesize that this reﬂects
contamination.
Citation: Blood Cancer Journal (2011) 1, e9; doi:10.1038/bcj.2011.7
& 2011 Macmillan Publishers Limited All rights reserved 2044-5385/11
www.nature.com/bcjsample suggests that the R882H mutation was somatic (Figure 1,
patient 68).
A ﬁnal patient (52) also possessed a R882H mutation, but this
could not be proved to be somatic because of contamination in
the buccal swab and was thus inconclusive.
The contamination of the buccal swab raises an important
discussion point. Of note Yamashita et al. used T cells and
Ley et al. used skin biopsies as a source of germline DNA for their
patients and reported that all of the DNMT3a mutations were
somatically acquired within the bone marrow.
1,2 Our varied
results using different buccal samples for patient 37 and the
altered frequency of mutation in patient 68 suggest that buccal
swabs may not be a pure population of non-hematopoietic cells
and that multiple swabs should be analyzed with clearly deﬁned
sequence ratios before deciding whether a mutation is germline.
The mutations we describe here are identical to those
previously described in AML. Yamashita et al. suggested that
R882H mutations decreased the activity of DNMT3a and Ley
et al. reported that there were 182 genomic regions with
signiﬁcantly altered methylation in R882H mutants as compared
with matched AML genomes from patient’s with wild-type
DNMT3a.
1 Ley et al. also found that R882 mutations were
associated with a worse prognosis in AML patients.
2 Taken
together these data suggest that R882 mutations are associated
with altered activity in DNMT3a. We now show that these
alterations are present in MDS before development of frank
leukemia. Future studies will help to illuminate the effect that
these changes have on gene function, genomic methylation and
overall expression patterns. The presence of these mutations
before leukemic transformation may become a useful prognostic
marker of likelihood of progression and of poor prognosis
although additional study is needed to clarify this.
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Figure 1 Sequencing results for patient 37, 52 and 68. Patient 52 harbors a heterozygous somatic mutation in amplicon 7 in bone marrow
specimens. Patient 37 harbors heterozygous somatic mutations in amplicons 3 and 7 in bone marrow with reduced frequency in the ﬁrst buccal
swab and no mutation in the second buccal swab. Patient 68 harbors a heterozygous somatic mutation in amplicon 7 in bone marrow specimens
with reduced frequency in the buccal swab.
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